0001225208-21-003518.txt : 20210223
0001225208-21-003518.hdr.sgml : 20210223
20210223171227
ACCESSION NUMBER: 0001225208-21-003518
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20210221
FILED AS OF DATE: 20210223
DATE AS OF CHANGE: 20210223
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Fitzgerald Joseph Michael
CENTRAL INDEX KEY: 0001484186
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-11083
FILM NUMBER: 21666735
MAIL ADDRESS:
STREET 1: C/O BOSTON SCIENTIFIC
STREET 2: 300 BOSTON SCIENTIFIC WAY
CITY: MARLBOROUGH
STATE: MA
ZIP: 01752-1234
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: BOSTON SCIENTIFIC CORP
CENTRAL INDEX KEY: 0000885725
STANDARD INDUSTRIAL CLASSIFICATION: SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841]
IRS NUMBER: 042695240
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 300 BOSTON SCIENTIFIC WAY
CITY: MARLBOROUGH
STATE: MA
ZIP: 01752-1234
BUSINESS PHONE: 508-683-4000
MAIL ADDRESS:
STREET 1: 300 BOSTON SCIENTIFIC WAY
CITY: MARLBOROUGH
STATE: MA
ZIP: 01752-1234
4
1
doc4.xml
X0306
4
2021-02-21
0000885725
BOSTON SCIENTIFIC CORP
BSX
0001484186
Fitzgerald Joseph Michael
300 BOSTON SCIENTIFIC WAY
MARLBOROUGH
MA
01752-1234
1
EVP & Pres, Interven Cardio
Common Stock
2021-02-21
4
M
0
3894.0000
0.0000
A
248824.0000
D
Common Stock
2021-02-21
4
F
0
1922.0000
38.0300
D
246902.0000
D
Common Stock
2021-02-22
4
M
0
4056.0000
0.0000
A
250958.0000
D
Common Stock
2021-02-22
4
F
0
2002.0000
39.2000
D
248956.0000
D
Common Stock
68312.0000
I
By 401(k)
Common Stock
6038.0000
I
By Children
Deferred Stock Units
2021-02-21
4
M
0
3894.0000
0.0000
D
2023-02-21
Common Stock
3894.0000
7790.0000
D
Deferred Stock Units
2021-02-22
4
M
0
4056.0000
0.0000
D
2021-02-22
Common Stock
4056.0000
0.0000
D
Performance Share Units
2021-02-22
4
A
0
13134.0000
0.0000
A
2022-12-31
2022-12-31
Common Stock
13134.0000
13134.0000
D
Each deferred stock unit represents the Company's commitment to issue one share of Boston Scientific common stock.
Balance reflects the most current data available with regard to share holdings in the Company's 401(k) Retirement Savings Plan.
The reporting person disclaims beneficial ownership of the shares held by his children, and this report should not be deemed an admission that the reporting person is the beneficial owner of his children's shares for purposes of Section 16 or for any other purpose.
Shares of common stock will be issued to the reporting person in four equal annual installments beginning on February 21, 2020, the first anniversary of the date of grant.
Shares of common stock will be issued to the reporting person in five equal annual installments beginning on February 22, 2017, the first anniversary of the date of grant.
Each performance share unit represents the Company's commitment to issue one share of Boston Scientific common stock.
On February 18, 2020, the reporting person was awarded a target number of performance share units under the Company's 2020 Free Cash Flow Performance Share Program, the actual number of which to be earned by the reporting person would be based on the Company's 2020 adjusted free cash flow measured against its 2020 financial plan over the one-year performance period ending December 31, 2020 and subject to the completion of a three-year individual service period (inclusive of the performance period). On February 22, 2021, the number of the target performance share units as to which the performance criteria had been satisfied was determined. The performance share units so determined will vest in whole upon the completion of the individual service period that ends on December 31, 2022.
/s/ Scott G. Hodgdon, Attorney-in-Fact
2021-02-23